415.14
-0.84 (-0.20%)
| Previous Close | 415.98 |
| Open | 431.86 |
| Volume | 413,549 |
| Avg. Volume (3M) | 496,832 |
| Market Cap | 33,993,617,408 |
| Price / Earnings (TTM) | 40.07 |
| Price / Earnings (Forward) | 36.10 |
| Price / Sales | 8.89 |
| Price / Book | 20.70 |
| 52 Weeks Range | |
| Earnings Date | 3 Feb 2025 - 7 Feb 2025 |
| Profit Margin | 22.53% |
| Operating Margin (TTM) | 37.46% |
| Diluted EPS (TTM) | 10.35 |
| Quarterly Revenue Growth (YOY) | 6.60% |
| Quarterly Earnings Growth (YOY) | 9.70% |
| Total Debt/Equity (MRQ) | 61.70% |
| Current Ratio (MRQ) | 1.42 |
| Operating Cash Flow (TTM) | 916.83 M |
| Levered Free Cash Flow (TTM) | 792.04 M |
| Return on Assets (TTM) | 22.79% |
| Return on Equity (TTM) | 59.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | IDEXX Laboratories, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.94% |
| % Held by Institutions | 94.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fundsmith Investment Services Ltd. | 30 Jun 2024 | 863,162 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 575.00 (JP Morgan, 38.51%) | Buy |
| Median | 500.00 (20.44%) | |
| Low | 435.00 (Piper Sandler, 4.78%) | Hold |
| Average | 498.20 (20.01%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 441.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 02 Dec 2024 | 500.00 (20.44%) | Buy | 430.77 |
| Barclays | 04 Nov 2024 | 481.00 (15.86%) | Buy | 414.52 |
| Piper Sandler | 04 Nov 2024 | 435.00 (4.78%) | Hold | 414.52 |
| JP Morgan | 11 Oct 2024 | 575.00 (38.51%) | Buy | 476.27 |
| Stifel | 10 Oct 2024 | 500.00 (20.44%) | Hold | 473.28 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2024 | Announcement | SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX |
| 09 Dec 2024 | Announcement | IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization |
| 21 Nov 2024 | Announcement | IDEXX Announces CFO Transition |
| 31 Oct 2024 | Announcement | CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results |
| 30 Sep 2024 | Announcement | IDEXX Laboratories to Release 2024 Third Quarter Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |